대한약학회:학술대회논문집 (Proceedings of the PSK Conference)
- 대한약학회 2002년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2
- /
- Pages.253.1-253.1
- /
- 2002
Comparison of CYP 3A4 metabolism between DA-8159 and Sildenafil in vitro and in vivo
- Park, Kyung-Jin (Research Laboratories. Dong-A Pharmaceutical Co., Ltd.) ;
- Youn, Hae-Sun (Research Laboratories. Dong-A Pharmaceutical Co., Ltd.) ;
- Shim, Hyun-Joo (Research Laboratories. Dong-A Pharmaceutical Co., Ltd.) ;
- Kim, Soon-Hoe (Research Laboratories. Dong-A Pharmaceutical Co., Ltd.) ;
- Yoo, Moo-Hi (Research Laboratories. Dong-A Pharmaceutical Co., Ltd.) ;
- Kim, Won-Bae (Research Laboratories. Dong-A Pharmaceutical Co., Ltd.)
- 발행 : 2002.10.01
초록
DA-8159 is a new PDEV inhibitor, synthesized by Dong-A Pharm, as an oral agent to treat male erectile dysfunction. DA-8159 and sildenafil are mainly metabolized by cytochrome P450 enzyme CYP 3A4. In this study. we compared the metabolism of DA-8159 with sildenafil in vitro and in vivo. First, we quantified the remaining gatio of original compound, DA-8159 and sidenafil., after we incubated drugs for 30 minutes with human liver microsome cytochrome P 450 3A4. (omitted)
키워드